Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy?
Tingkai Chen(China Pharmaceutical University), Haopeng Sun(China Pharmaceutical University), Zongliang Liu(Anhui Agricultural University), Qi Li(Qingdao University), Yao Chen(Nanjing University of Chinese Medicine), Feng Feng(Nanjing Medical University)
Cited by 99
Related Papers
Degradation of proteins by PROTACs and other strategies
|Acta Pharmaceutica Sinica B|2019|312
Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease
|European Journal of Medicinal Chemistry|2017|307
Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms
|Journal of Medicinal Chemistry|2019|270
Donepezil-based multi-functional cholinesterase inhibitors for treatment of Alzheimer's disease
|European Journal of Medicinal Chemistry|2018|200
Strategies for Structural Modification of Small Molecules to Improve Blood–Brain Barrier Penetration: A Recent Perspective
|Journal of Medicinal Chemistry|2021|196